Oncorena's FDA Approval Signals a New Beginning for Treatments
Oncorena is thrilled to announce a groundbreaking milestone, as the FDA has approved the Company’s IND application. This approval enables Oncorena to initiate the Phase I/II study known as Oncorella-1. This pivotal study will closely evaluate the safety, tolerability, and anti-tumor efficacy of orellanine treatment in patients facing metastatic clear-cell or papillary renal cell carcinoma.
About the Oncorella-1 Study
The Oncorella-1 study plans to enroll up to 75 patients battling severe metastatic renal cancer who are in urgent need of new therapies. These individuals have typically exhausted all other treatment options available to them. The investigational drug, ONC175, could potentially represent a groundbreaking first-in-class treatment aimed at addressing their critical medical needs.
Leading the Charge in Cancer Treatment
The exciting research is set to take place at Karolinska University Hospital. Börje Haraldsson, CEO and co-founder of Oncorena, commented on this pivotal moment, stating that this approval positions them closer to evaluating a truly novel treatment option. They are particularly excited about establishing the first U.S. study site, under the guidance of Professor Nizar Tannir, a globally recognized authority in renal cancer.
Understanding ONC175 and Its Mechanism
ONC175 is an investigational drug that operates through synthetically produced orellanine, a compound that uniquely targets the kidneys, leading to specific actions that induce renal failure, while sparing other organs. This specificity is a critical factor in its potential effectiveness. In prior pioneering studies, ONC175 has demonstrated a compelling ability to eliminate human metastatic renal cancer cells while exhibiting a powerful organ-specific mechanism of action.
Development Goals for ONC175
The main ambition behind the development of ONC175 is to find a potential curative solution for patients suffering from metastatic renal cell carcinoma who currently have no kidney function left and are on dialysis. This approach aims to usher in a new era of hope for those whose treatment options have diminished significantly.
Kidney Cancer: A Critical Health Concern
Kidney cancer, recognized as a significant global health issue, affects approximately 400,000 individuals worldwide, according to the latest reports from health organizations. If detected early, surgery can often eradicate the disease; however, the prognosis deteriorates if the cancer metastasizes. Existing treatments typically consist of targeted and immuno-active drugs, which often fail to provide a cure. Hence, an urgent unmet medical need exists for more effective and safer alternatives.
Contact For More Information
For those interested in learning more about this innovative study or the company, Börje Haraldsson, M.D., Ph.D., who serves as the CEO and CSO of Oncorena AB, is available for inquiries. Although specific email addresses for direct contact are not listed here, potential inquiries can be made through other communication methods provided by Oncorena.
Frequently Asked Questions
What is Oncorella-1?
Oncorella-1 is a Phase I/II study evaluating the safety and efficacy of ONC175 in patients with metastatic renal cancer.
Who is leading the study?
Professor Nizar Tannir, an expert in renal cancer, is the lead investigator at the U.S. trial site.
What is ONC175?
ONC175 is an investigational drug that contains orellanine, which specifically targets the kidneys.
How many patients will be enrolled in the study?
Up to 75 patients will be enrolled in the Oncorella-1 study.
Why is there a need for new kidney cancer treatments?
Current treatments often fail to cure advanced kidney cancer, making new effective drugs critically important for patients with limited options.
